Background illustration for clinical trials search

Paid Clinical Trials Springfield

Discover 125 paid clinical trials in Springfield, Missouri. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 125

Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design

for

Fibromyalgia

Location: Springfield MO, Overland Park KS, Kansas City KS,

Sponsor: Axsome Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT07398417

Phase3, Recruiting

A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in Adults

for

Chronic Idiopathic Constipation (CIC)

Location: Springfield MO, Columbia Falls MT, Overland Park KS,

Sponsor: Ardelyx

Sex: All

Age: 18 - 70+

Code: NCT07382167

Phase3, Recruiting

AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer

for

Epithelial Ovarian Cancer

Location: Springfield MO, Germantown TN, Peoria IL, Omaha NE,

Sponsor: AstraZeneca

Sex: Female

Age: 18+

Code: NCT07218809

Phase3, Recruiting

Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

for

Metastatic Colorectal Cancer (CRC)

Location: Springfield MO, Westwood KS, O'Fallon IL, Germantown TN,

Sponsor: Summit Therapeutics

Sex: All

Age: 18+

Code: NCT07228832

Phase3, Recruiting

A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients

for

Untreated Follicular Lymphoma

Location: Springfield MO, Huntsville AL, Fort Wayne IN, Macon GA,

Sponsor: AstraZeneca

Sex: All

Age: 18 - 70+

Code: NCT06549595

Phase3, Recruiting

A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event

for

Cardiovascular Disease

Location: Springfield MO, Jefferson City MO, Kansas City MO,

Sponsor: AstraZeneca

Sex: All

Age: 18+

Code: NCT07000357

Phase3, Recruiting

Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

for

Advanced Breast Cancer

Location: Springfield MO, Saint Joseph MO, Urbana IL,

Sponsor: AstraZeneca

Sex: All

Age: 18+

Code: NCT06380751

Phase3, Recruiting

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

for

Endometrial Cancer

Location: Springfield MO, Little Rock AR, St Louis MO,

Sponsor: AstraZeneca

Sex: Female

Age: 18+

Code: NCT06989112

Phase3, Recruiting

A RETROspective Data Collection of comPRESSion Anastomosis Using the ColonRing

for

Diverticulum, Colon, Colorectal Neoplasms, Crohn Disease,

Location: Springfield MO, Atlamonte Springs FL, Port Charlotte FL

Sponsor: novoGI

Sex: All

Age: 18+

Code: NCT01880918

Recruiting

A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

for

Hormone Receptor Positive HER-2 Negative Breast Cancer,

Location: Springfield MO, Columbia MO, Kansas City MO,

Sponsor: Puma Biotechnology, Inc.

Sex: All

Age: 18+

Code: NCT06369285

Phase2, Recruiting

TEMPUS ARIES: A Biobank Registry Platform Study in Oncology

for

Cancer

Location: Springfield MO, Osage Beach MO, Hannibal MO,

Sponsor: Tempus AI

Sex: All

Age: 18 - 70+

Code: NCT06207032

Recruiting

A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)

for

Head and Neck Squamous Cell Carcinoma

Location: Springfield MO, Westwood KS, St Louis MO, Decatur IL,

Sponsor: Tempus AI

Sex: All

Age: 18+

Code: NCT06163534

Recruiting

Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies

for

Breast Cancer, TNBC - Triple-Negative Breast Cancer,

Location: Springfield MO, O'Fallon IL, Carbondale IL,

Sponsor: Tempus AI

Sex: All

Age: 18 - 70+

Code: NCT07211178

Recruiting

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

for

Large B-cell Lymphoma

Location: Springfield MO, Columbia MO, Kansas City MO,

Sponsor: Allogene Therapeutics

Sex: All

Age: 18+

Code: NCT06500273

Phase2, Recruiting

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

for

Carcinoma, Non-Small-Cell Lung

Location: Springfield MO, Fairway KS, Kansas City MO, St Louis MO,

Sponsor: Janssen Research & Development, LLC

Sex: All

Age: 18+

Code: NCT06667076

Phase2, Recruiting

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

for

Carcinoma, Transitional Cell, Urinary Bladder Neoplasms,

Location: Springfield MO, St Louis MO, Tyler TX, Dallas TX,

Sponsor: Eli Lilly and Company

Sex: All

Age: 18+

Code: NCT07218380

Phase3, Recruiting

BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease

for

HR+/HER2- Breast Cancer

Location: Springfield MO, Hot Springs AR, OFallon IL, Lincoln NE,

Sponsor: BeOne Medicines

Sex: All

Age: 18+

Code: NCT07492641

Phase3, Recruiting

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

for

Breast Neoplasms, Neoplasm Metastasis

Location: Springfield MO, Springdale AR, Tupelo MS, Dallas TX,

Sponsor: Eli Lilly and Company

Sex: All

Age: 18+

Code: NCT07174336

Phase3, Recruiting

A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

for

CLL, Chronic Lymphocytic Leukemia

Location: Springfield MO, Jonesboro AR, Chesterfield MO, Omaha NE,

Sponsor: BeOne Medicines

Sex: All

Age: 18+

Code: NCT06846671

Phase3, Recruiting

A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

for

CRC (Colorectal Cancer)

Location: Springfield MO, Columbia MO, Kansas City MO,

Sponsor: Incyte Corporation

Sex: All

Age: 18+

Code: NCT07284849

Phase3, Recruiting

Paid Clinical Trials Springfield

Filter results

Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design

A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in Adults

AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer

Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients

Interested in new trials?

A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event

Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

A RETROspective Data Collection of comPRESSion Anastomosis Using the ColonRing

A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

TEMPUS ARIES: A Biobank Registry Platform Study in Oncology

A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)

Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer